Brief: The Oncology Institute Enrolls Nation’S First Two Patients In A Phase 3 Open-Label, Randomized Clinical Trial Of Pirtobrutinib

Starling Oncology

29/09/2022 13:27

Sept 29 (Reuters) - Oncology Institute Inc  TOI.O :
    * THE ONCOLOGY INSTITUTE ENROLLS NATION’S FIRST TWO PATIENTS
IN A
PHASE 3 OPEN-LABEL, RANDOMIZED CLINICAL TRIAL OF PIRTOBRUTINIB
    * ONCOLOGY INSTITUTE INC - ELI LILLY AND COMPANY SERVES AS
SPONSOR
OF THIS CLINICAL TRIAL

Source text for Eikon:  ID:nGNX1PTr0C 
Further company coverage:  TOI.O 
 ((Reuters.Briefs@thomsonreuters.com;))